PMGC Holdings

PMGC Holdings EBIT per Employee

The EBIT per Employee of PMGC Holdings (ELAB) as of Nov 6, 2026 is -457,541.88 USD. In the previous year, EBIT per Employee was -205,094.81 USD — a change of 123.09% (lower).

EBIT per Employee

-457,541.88USD

YoY

123.09%

Last updated:

EBIT per Employee of PMGC Holdings is 2025 -457,541.88 USD. EBIT per Employee of PMGC Holdings was 2024 -205,094.81 USD. It decreases by 123.09% lower compared to the previous year.

The PMGC Holdings EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2020
-13,865.25 USD
Jan 1, 2021
-49,066.38 USD
Jan 1, 2022
-111,768.25 USD
Jan 1, 2023
-102,673.63 USD
Jan 1, 2024
-205,094.81 USD
Jan 1, 2025
-457,541.88 USD
The PMGC Holdings EBIT per Employee history
YEAREBIT per EmployeeYoY
-457,541.88USD+123.09%
-205,094.81USD+99.75%
-102,673.63USD-8.14%
-111,768.25USD+127.79%
-49,066.38USD+253.88%
-13,865.25USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PMGC Holdings Stock analysis

What does PMGC Holdings do? ELEVAI Labs Inc generates revenue through its physician-dispensed skincare products, primarily featuring the Elevai Exosomes technology. The company's Precision Regenerative Exosome Technology (PREx) produces exosome lots from human umbilical cord-derived mesenchymal stem cells for its specialty products. Its initial product line, Elevai Post Treatment E-Series, includes Empower and Enfinity serums designed for post-skincare procedure care targeting the face, neck, and upper chest. The products are sold directly to physicians who dispense them to patients as part of medical aesthetics treatments. The company focuses on the medical aesthetics industry, where its products complement professional skincare procedures. Physicians purchase Elevai's serums to offer patients enhanced skin appearance solutions following treatments. The E-Series targets specific areas requiring post-procedure care, with Empower supporting healthy skin appearance and Enfinity providing specialized care for the face, neck, and upper chest regions. The firm's research and development efforts drive the commercialization of these science-driven topical skincare solutions. ELEVAI Labs Inc's business model centers on physician-dispensed products within the medical aesthetics sector. The company's proprietary PREx biotechnology process enables the production of exosome-based skincare, which is integrated into its initial product line. The products are marketed as complementary solutions for patients undergoing medical aesthetic procedures, with physicians acting as the primary buyers who distribute them to end users. PMGC Holdings is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PMGC Holdings stock

EBIT per Employee of PMGC Holdings is -457,541.88 USD in 2025.

EBIT per Employee of PMGC Holdings changed from -205,094.81 USD to -457,541.88 USD, representing a 123.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee PMGC Holdings since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's PMGC Holdings historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — PMGC Holdings

All Key Metrics — PMGC Holdings